EVANSTON, Illinois, July 27 -- Northwestern University posted the following news release: * * * 'Bone-ified muscles' could be robots' next flex * * A new soft actuator moves and stiffens like biological muscle * The muscles, or actuators, are constructed from low-cost, 3D-printed rubbers * Engineers integrated three actuators as 'muscles' into a human-sized robotic leg with 3D-printed rigid 'bones' and elastic 'tendons' * The high-force, electrically driven actuators enabled kickin more PR

UNIVERSITY PARK, Pennsylvania, July 28 -- Pennsylvania State University posted the following news: * * * A bolt is born! Atmospheric events underpinning lightning strikes explained * UNIVERSITY PARK, Pa. -- Though scientists have long understood how lightning strikes, the precise atmospheric events that trigger it within thunderclouds remained a perplexing mystery. The mystery may be solved, thanks to a team of researchers led by Victor Pasko, professor of electrical engineering in the Penn  more PR

SAN JOSE, California, July 29 -- Cadence Design Systems, a provider of electronic design automation and semiconductor intellectual property, issued the following news release on July 28, 2025: * * * Cadence Reports Second Quarter 2025 Financial Results Exceeded Q2 Guidance for Revenue & Non-GAAP EPS Raising 2025 Revenue, Non-GAAP EPS & Cash Flow Outlook * SAN JOSE, Calif.-- Cadence (Nasdaq: CDNS) today announced results for the second quarter of 2025. Second Quarter 2025 Financial Results more PR

CAMBRIDGE, Massachusetts, July 28 -- The Massachusetts Institute of Technology issued the following news: * * * Famous double-slit experiment holds up when stripped to its quantum essentials * MIT physicists have performed an idealized version of one of the most famous experiments in quantum physics. Their findings demonstrate, with atomic-level precision, the dual yet evasive nature of light. They also happen to confirm that Albert Einstein was wrong about this particular quantum scenario.  more PR

WILMINGTON, Delaware, July 29 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * IMFINZI (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit If approved, this will be the first and only perioperati more PR